adMare
News

News - Thumbnail

October 02 2024

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment 

Read
News - Thumbnail

September 20 2024

adMare BioInnovations Appoints Marc Rivière to its Board of Directors

 

Read
News - Thumbnail

September 18 2024

NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases

Read
News - Thumbnail

September 16 2024

Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec

Read
News - Thumbnail

September 05 2024

Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma

Read
News - Thumbnail

September 04 2024

PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada

Read
News - Thumbnail

September 03 2024

SOFIAC Canada enables decarbonization of adMare BioInnovations' buildings with a $3.275M investment

Read
News - Thumbnail

August 14 2024

adMare BioInnovations Opens Applications for the Fall Cohorts of the BioInnovation Scientist Programs 

 

Read
News - Thumbnail

June 27 2024

adMare BioInnovations Expands with New Wet Laboratory Space in Vancouver

 

Read
News - Thumbnail

June 11 2024

adMare Academy Opens Applications for Cohort VII of its Executive Institute 

Read
News - Thumbnail

May 21 2024

adMare BioInnovations Welcomes Five New Start-Ups in the National Tx Accelerator 

Read
News - Thumbnail

February 20 2024

adMare BioInnovations Opens Applications for the Spring 2024 Cohort of the BioInnovation Scientist Program: Foundations and Launches New Biopharma Industry Essentials Program 

 

Read